Investors and Media
  Events, Presentations and Webcasts
Press Releases
  Bionovo in the News
  Stock Details
  Analyst Coverage
  SEC Filings
  SEC Filings - XBRL Content
  Corporate Governance


$N/A (N/A)


Press Release


Printer Friendly Version View printer-friendly version

Dr. Richard Weiner, Ph.D., Joins Bionovo Scientific Advisory Board

EMERYVILLE, Calif., May 27, 2010 /PRNewswire via COMTEX/ --Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of Dr. Richard I. Weiner, Ph.D., to the company's Scientific Advisory Board. Dr. Weiner is an Emeritus Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco, School of Medicine, and is a renowned authority on neuroendocrinology and cancer research.

"We are honored to have Dr. Weiner join our Scientific Advisory Board, given his well established expertise in the fields of neuroendocrine regulation of female reproduction and tumor angiogenesis. Dr. Weiner has over forty years of experience in these fields, and has particular expertise in the areas of signaling pathways and hormonal regulation of the neuronal pathways regulating the menstrual cycle, areas of great interest to Bionovo," said Isaac Cohen, OMD, Bionovo's Chairman and Chief Executive Officer.

Dr. Weiner states, "Bionovo has had remarkable success in bringing important scientific work to bear on meeting significant unmet medical needs. It will be gratifying to work with Bionovo, and to be given a chance to participate in the development of such important drug therapies."

Dr. Weiner holds bachelor's and master's degrees from Pennsylvania State University, and holds a doctoral degree from the University of California, San Francisco and did postdoctoral work at UCLA. He previously held positions of distinction at the University of Tennessee, the University of Southern California and the Salk Institute. Dr. Weiner has over 275 publications spanning forty years.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE Bionovo, Inc.